SuperworthLexeo Therapeutics LXEO
- Market cap
- $229.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −38.6%
Lexeo Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $17.2M+12% | $8.2M−28% | $15.7M−4% | $16.6M+47% | $23.4M+36% | $18.4M+124% | $17.2M+9% | $14.7M−11% | $15.7M−33% | $16.2M−12% | $15.7M−9% | $19M+29% |
| SG&A | $3M+14% | $6.8M+78% | $7.5M+165% | $7M+155% | $8.1M+168% | $9M+33% | $16.6M+120% | $16M+128% | $6M−27% | $6.9M−23% | $6.6M−60% | $9M−44% |
| −$20.3M+16% | −$15M−2% | −$23.3M+21% | −$23.6M+69% | −$31.5M+56% | −$27.4M+83% | −$33.8M+45% | −$30.7M+30% | −$21.6M−31% | −$23.1M−16% | −$22.3M−34% | −$28M−9% | |
| Interest expense | $52K+79% | $50K−7% | $37K−26% | $35K−34% | $35K−33% | $30K−40% | $28K−24% | $25K−29% | $22K−37% | $20K−33% | $17K−39% | $14K−44% |
| Pre-tax income | −$20.1M+18% | −$14.2M−3% | −$21.7M+16% | −$21.2M+58% | −$29.5M+47% | −$25.9M+83% | −$32.7M+51% | −$26.1M+23% | −$20.3M−31% | −$20.9M−19% | −$20.2M−38% | −$25.9M−1% |
| Net income | −$20.1M+18% | −$14.2M−3% | −$21.7M+16% | −$21.2M+58% | −$29.5M+47% | −$25.9M+83% | −$32.7M+51% | −$26.1M+23% | −$20.3M−31% | −$20.9M−19% | −$20.2M−38% | −$25.9M−1% |
| −$12.36+19% | n/a | −$0.77−93% | −$0.64−92% | −$0.89−93% | −$0.78 | −$0.99+29% | −$0.60−6% | −$0.33−63% | −$0.27−65% | −$0.25−75% | −$0.30−50% | |
| 1.6M−1% | n/a | 28M+1637% | 33M+1938% | 33.1M+1933% | 33.1M | 33.1M+18% | 43.6M+32% | 61M+84% | 76.4M+131% | 81.2M+145% | 85.6M+97% |
EPS, diluted: 3 periods, Q4 FY22 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY22 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Lexeo Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LXEOLexeo Therapeutics | $229.7M | n/m | n/a | n/m | n/m | n/m | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| Peer median | $884.6M | 13.0× | 34.2× | 2.5× | +27% | 19.9% |
More on Lexeo Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .